drugset / Trial / NCT06469151

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

NCT06469151 ↗

Phase 1 Completed 84 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants

Timeline

Start
2024-06-24
Primary completion
2025-10-22
Completion
2025-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5148 Monoclonal antibody — Intramuscular

Indications

No indication recorded.